Brief: Adaptimmune Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq
16/02/2024 21:41
Feb 16 (Reuters) - Adaptimmune Therapeutics PLC
ADAP.O :
* ADAPTIMMUNE THERAPEUTICS: GOT LETTER FROM NASDAQ THAT CO
HAS
REGAINED COMPLIANCE WITH MINIMUM BID PRICE REQUIREMENT FOR
CONTINUED LISTING ON NASDAQ
Source text for Eikon: ID:n0001558370-24-001304
Further company coverage: ADAP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Adaptimmune Therapeutics
See all newsAdaptimmune Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 10 cents a share - Earnings Preview
Enters Settlement Agreement With MD Anderson - SEC Filing
Adaptimmune Therapeutics PLC reports results for the quarter ended March 31 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 12 cents a share - Earnings Preview